Clinical Trial Update: Evaluation of [18F]APN-1607 as a PET Biomarker [Phase 1]

View source ↗

Summary

Phase 1 trial updates report evaluation of the PET biomarker [18F]APN-1607 in Progressive Supranuclear Palsy and healthy volunteers. The study status is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• [18F]APN-1607 (APN-1607)

Snippet

Sponsor: Invicro | Conditions: Progressive Supranuclear Palsy, Healthy Volunteers | Phase 1 | Status: COMPLETED